Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems

Lara Chilver-Stainer; Bernhard Lämmle; Lorenzo Alberio

doi:10.1160/TH03-07-0454

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 91(02): 276-282
DOI: 10.1160/TH03-07-0454

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems

Lara Chilver-Stainer

¹Central Haematology Laboratory, University Hospital Inselspital, Bern, Switzerland

,

Bernhard Lämmle

¹Central Haematology Laboratory, University Hospital Inselspital, Bern, Switzerland

,

Lorenzo Alberio

¹Central Haematology Laboratory, University Hospital Inselspital, Bern, Switzerland

› Author Affiliations

Abstract

Summary

Heparin-induced thrombocytopenia (HIT) is mediated by antibodies directed against the heparin/platelet factor 4 (PF4) complex. Our aim was to investigate whether the antibody titre is associated with the degree of in vivo thrombin generation. We measured the anti-heparin/PF4-antibody titre, prothrombin fragments F1+2, thrombin-antithrombin (TAT) complexes and D-dimers in plasma samples from 225 patients with suspected HIT. Antibody titres as detected by a particle gel immunoassay strongly correlated with optical density values measured by ELISA (r=0.84, p<0.0001). Patients with titres ≥ 4 (n=44) had significantly higher median levels of F1+2 (2.49 nmol/l), TAT (13.01 µg/l) and D-dimers (3340 µg/l) compared to patients with undetectable antibodies (n=148; F1+2 1.61 nmol/l, TAT 4.95 µg/l, D-dimers 1911 µg/l; p<0.0001 for all comparisons) or patients with titres of 1-2 (n=33; F1+2 1.44 nmol/l, p=0.0014; TAT 4.37 µg/l, p=0.0018; D-dimers 2231 µg/l, p=0.0016). Multivariate analysis indicated the anti-heparin/PF4-antibody titre as an independent predictor for F1+2 (p=0.0036), TAT (p=0.0176) and D-dimer (p=0.0003) levels. This relationship remained statistically significant after exclusion of patients with concomitant prothrombotic conditions and/or thromboembolic complications during heparin treatment. These data demonstrate that high anti-heparin/PF4-antibody titres are independently associated with an increased in vivo thrombin generation. Rapid determination of the anti-heparin/PF4-antibody titre could help guide clinical management, identifying a subset of HIT-patients who are at high risk of developing thromboembolic complications and possibly require alternative anticoagulation in therapeutic dosage even in the context of isolated HIT.

Keywords

Heparin - anti-heparin/PF4 antibody - titre - F1+2 - TAT - D-dimer

Full Text

References

References
1 Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
2 Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular- weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
3 Warkentin TE, Sheppard JA, Horsewood P. et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-8.
4 Chong BH, Pitney WR, Castaldi PA. Heparininduced thrombocytopenia: association of thrombotic complications with heparindependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 1982; 02: 1246-9.
5 Warkentin TE, Elavathil LJ, Hayward CP. et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-12.
6 Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7.
7 Nand S, Wong W, Yuen B. et al. Heparininduced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56: 12-6.
8 Zalcberg JR, McGrath K, Dauer R. et al. Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation. Br J Haematol 1983; 54: 655-7.
9 Amiral J, Bridey F, Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6.
10 Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000; 96: 182-7.
11 Herbert JM, Savi P, Jeske WP. et al. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 1998; 80: 326-31.
12 Warkentin TE, Hayward CP, Boshkov LK. et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
13 Pouplard C, Iochmann S, Renard B. et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97: 3300-2.
14 Lee DH, Warkentin TE, Denomme GA. et al. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia. Thromb Haemost 1998; 79: 50-3.
15 Brandt JT, Isenhart CE, Osborne JM. et al. On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564-72.
16 Walenga JM, Jeske WP, Messmore HL. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2000; 10 (Suppl. 01) 13-20.
17 Ahmad S, Walenga JM, Jeske WP. et al. Functional heterogeneity of antiheparinplatelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost 1999; 5 (Suppl. 01) S32-7.
18 Lindhoff-Last E, Gerdsen F, Ackermann H. et al. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparininduced thrombocytopenia. Br J Haematol 2001; 113: 886-90.
19 Meyer O, Salama A, Pittet N. et al. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet 1999; 354: 1525-6.
20 Alberio L, Kimmerle S, Baumann A. et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 2003; 114: 528-36.
21 Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-9.
22 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzymelinked immunosorbent assay. Thromb Haemost 1988; 59: 101-6.
23 de Moerloose P, Bounameaux H, Perrier A. et al. Performances of the VIDAS D-dimer new assay for the exclusion of venous thromboembolism. Thromb Haemost 2001; 85: 185-6.
24 Greinacher A, Amiral J, Dummel V. et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 381-5.
25 Stricker H, Lammle B, Furlan M. et al. Heparin-dependent in vitro aggregation of normal platelets by plasma of a patient with heparin-induced skin necrosis: specific diagnostic test for a rare side effect. Am J Med 1988; 85: 721-4.
26 Visentin GP, Moghaddam M, Collins JL. et al. Antibodies associated with heparin-induced thrombocytopenia (HIT) report conformational changes in platelet factor 4 (PF4) induced by linear polyanionic compounds (abstract). Blood 1997; 90: 460a.
27 Suh JS, Malik MI, Aster RH. et al. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997; 54: 196-201.
28 Fabris F, Luzzatto G, Soini B. et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med 2002; 252: 149-54.
29 Walenga JM, Jeske WP, Fasanella AR. et al. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1999; 5 (Suppl. 01) S21-7.
30 Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 02: 148-57.
31 Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61.
32 Greinacher A, Volpel H, Janssens U. et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80.
33 Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997; 23: 197-202.
34 Warkentin TE. Heparin-induced thrombocytopenia: yet another treatment paradox?. Thromb Haemost 2001; 85: 947-9.
35 Wallis DE, Workman DL, Lewis BE. et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629-35.
36 Tardy B, Tardy-Poncet B, Fournel P. et al. Lower limb veins should be systematically explored in patients with isolated heparininduced thrombocytopenia. Thromb Haemost 1999; 82: 1199-200.
37 Farner B, Eichler P, Kroll H. et al. A comparison of danaparoid and lepirudin in heparininduced thrombocytopenia. Thromb Haemost 2001; 85: 950-7.